Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.
Sirolimus is a new immunosuppressive agent increasingly being used in liver transplant recipients. There is concern that sirolimus may be associated with wound complications and hepatic artery thrombosis (HAT). We have used sirolimus as primary immunosuppression in 170 liver transplant recipients and therefore reviewed our experience with wound complications and HAT in our cohort of patients. Records of all 170 patients administered sirolimus as primary immunosuppression and 180 historic controls were reviewed. Numbers of wound and hepatic artery complications were recorded, as well as the prevalence of obesity, reoperation, diabetes, and OKT3 use, all of which are risk factors for wound complications. The prevalence of wound complications was 12.4% in sirolimus-treated patients compared with 13.9% in historic controls (P = not significant [NS]). The prevalence of hepatic artery complications was 5.3% in sirolimus-treated patients compared with 8.3% in historic controls (P = NS). The prevalence of obesity and OKT3 administration was significantly lower in sirolimus-treated patients. Multivariate analysis failed to show an association between sirolimus therapy and hepatic artery or wound complications. The prevalence of wound and hepatic artery complications is not different in liver transplant recipients administered sirolimus as part of a primary immunosuppressive regimen compared with historic controls.
Dunkelberg
Jeffrey C
JC
Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA.
Trotter
James F
JF
Wachs
Michael
M
Bak
Thomas
T
Kugelmas
Marcello
M
Steinberg
Tracy
T
Everson
Gregory T
GT
Kam
Igal
I
D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000453:epidemiology; D006499:Hepatic Artery; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016853:Muromonab-CD3 / Q000008:administration & dosage; D009765:Obesity / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D015995:Prevalence; D012086:Reoperation; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D020123:Sirolimus